201 related articles for article (PubMed ID: 27650511)
21. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
[TBL] [Abstract][Full Text] [Related]
22. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome.
Bernal T; Diez-Campelo M; Godoy V; Rojas S; Colado E; Alcoceba M; González M; Vidriales B; Sánchez-Guijo FM; López-Corral L; Luño E; del Cañizo C
Leuk Res; 2014 May; 38(5):551-6. PubMed ID: 24655806
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion.
van der Reijden BA; Simons A; Luiten E; van der Poel SC; Hogenbirk PE; Tönnissen E; Valk PJ; Löwenberg B; De Greef GE; Breuning MH; Jansen JH
Br J Haematol; 2002 Aug; 118(2):411-8. PubMed ID: 12139724
[TBL] [Abstract][Full Text] [Related]
24. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.
Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
Eur J Haematol; 2013 Aug; 91(2):112-21. PubMed ID: 23672350
[TBL] [Abstract][Full Text] [Related]
25. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
26. [Inv(16)-type acute myeloid leukemia with repeated skin infiltration without bone marrow relapse before and after allogeneic hematopoietic stem cell transplantation].
Tokita K; Takahashi W; Arai H; Handa T; Nakamura Y; Maki K; Sasaki K; Mitani K
Rinsho Ketsueki; 2013 Dec; 54(12):2203-6. PubMed ID: 24452154
[TBL] [Abstract][Full Text] [Related]
27. KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.
Zhao L; Melenhorst JJ; Alemu L; Kirby M; Anderson S; Kench M; Hoogstraten-Miller S; Brinster L; Kamikubo Y; Gilliland DG; Liu PP
Blood; 2012 Feb; 119(6):1511-21. PubMed ID: 22160378
[TBL] [Abstract][Full Text] [Related]
28. Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia.
Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):958-66. PubMed ID: 23542687
[TBL] [Abstract][Full Text] [Related]
29. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
30. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
31. Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients.
Park SH; Chi HS; Cho YU; Jang S; Park CJ
Leuk Res; 2013 Jul; 37(7):784-9. PubMed ID: 23528260
[TBL] [Abstract][Full Text] [Related]
32. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
33. Cytogenetically normal acute myeloid leukemia with a novel KIT mutation in exon 11 G565V developing a sole trisomy 13 at relapse: a clinical dilemma.
Nieto MJ; Scalise A; Najfeld V
Acta Haematol; 2015; 133(1):1-5. PubMed ID: 24968822
[TBL] [Abstract][Full Text] [Related]
34. Minimal residual disease-directed therapy in acute myeloid leukemia.
Kayser S; Schlenk RF; Grimwade D; Yosuico VE; Walter RB
Blood; 2015 Apr; 125(15):2331-5. PubMed ID: 25631772
[No Abstract] [Full Text] [Related]
35. Hematopoietic cell transplantation for adults with acute myeloid leukemia with minimal residual disease.
Appelbaum FR
Best Pract Res Clin Haematol; 2015; 28(2-3):133-40. PubMed ID: 26590770
[TBL] [Abstract][Full Text] [Related]
36. Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice.
Saida S; Zhen T; Kim E; Yu K; Lopez G; McReynolds LJ; Liu PP
Leukemia; 2020 Mar; 34(3):759-770. PubMed ID: 31624376
[TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation.
Nanri T; Matsuno N; Kawakita T; Mitsuya H; Asou N
Leukemia; 2005 Sep; 19(9):1673-5. PubMed ID: 16049512
[No Abstract] [Full Text] [Related]
38. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
[TBL] [Abstract][Full Text] [Related]
39. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA
Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
[TBL] [Abstract][Full Text] [Related]
40. Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study.
Laczika K; Novak M; Hilgarth B; Mitterbauer M; Mitterbauer G; Scheidel-Petrovic A; Scholten C; Thalhammer-Scherrer R; Brugger S; Keil F; Schwarzinger I; Haas OA; Lechner K; Jaeger U
J Clin Oncol; 1998 Apr; 16(4):1519-25. PubMed ID: 9552061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
